Table 1.

A summary of previously reported cases of similar lesions due to PD-1 inhibitors.

No.	Author & Year	Disease	Treatment of disease	Lesions
1	Tembunde & Dika, 2023 (11)	Lung cancer	Pembrolizumab; 200 mg intravenous infusions every three weeks	The lesions started a week after beginning pembrolizumab for NSCLC, the lesion was intermittent, typically present for one to two weeks before resolving spontaneously.
2	Olsen et al, 2024 (10)	Recurrent metastatic oropharyngeal SCC1	Nivolumab	The lesions started after begin treatment with nivolumab 1 month, the patient was able to continue nivolumab infusions without significant interruption during the entire course of treatment for the KAs.
3	Fradet et al, 2019 (3)	Metastatic bronchial SCC1	Pembrolizumab	After treating for the second treatment cycle;developed hyper-keratotic nodular lesions (more than 30 lesions in total) on the dorsal region of his hands, knees and legs.
4	Crow et al, 2020 (12)	Metastatic melanoma	Pembrolizumab	Developed severely pruritic violaceous plaques on the trunk and extremities shortly after the initiation of pembrolizumab, concomitantly developed numerous scaly papules, plaques, and crateriform nodules on the extremities.
5	Crow et al, 2020 (12)	Metastatic mesothelioma	Pembrolizumab	Developed severely pruritic violaceous plaques on the trunk and extremities shortly after the initiation of pembrolizumab, concomitantly developed numerous scaly papules, plaques, and crateriform nodules on the extremities.
6	Crow et al, 2020 (12)	Metastatic lung adenocarcinoma	Nivolumab	Presented with pruritic, ill-defined scaly plaques on the trunk and extremities that were shown histopathologically to be spongiotic dermatitis, and numerous verrucous papules on the legs that were biopsy-proven KAs.

1, squamous cell carcinoma.